App-Quantinova.ai

Optimal Defibrillator Placement in a High-rise Building

Timothy C.Y. Chan - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Ranking Businesses and Municipal Locations by Spatiotemporal Cardiac Arrest Risk to Guide Public Defibrillator Placement

Steven C Brooks - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

Differential Role of Autophagy in Idiopathic versus Ischemic Heart Failure in Humans

Krishna K. Singh - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemia-reperfusion injury

N/A

Regional Variation in 30-Day Ischemic Stroke Mortality and Readmissions in Get With the Guidelines-Stroke Hospitals

Xin Zhao - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

The Canadian GENESIS Gender Index may be the Key to Understanding Differences in Health Status Outcomes in Acute Coronary Syndrome.

Nicole L. Johnson - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Progressive Diastolic Dysfunction, Perivascular Fibrosis and Left Ventricular Hypertrophy in LDL-Receptor Deficient Mice

Candace Lee - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left ventricular diastolic dysfunction

Angiotensin II

Systemic Loss of p62 Reduces Pressure Overload Induced Cardiac Hypertrophy, Dysfunction and Apoptosis

Khosrow Rezvani - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Lipoprotein(a) Stimulates Pro-Inflammatory Phenotypes in Vascular Cells: Demonstration of a Role for the Lysine-Binding Properties of Apolipoprotein(a)

Victor C Igbokwe - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Identification of Proteolytic Substrates for ADAMTS7 Using Terminal Amine Isotope Labeling of Substrates

Theo Klein - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Using Lean Methodology to Reduce Variation in Care of Acute Coronary Syndrome Patients

Guy Fradet - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Adropin Enhancement of Cardiac Insulin Sensitivity and Inhibition of Fatty Acid Oxidation are Associated With Improvement of Cardiac Function and Efficiency in Hearts From Fasted Mice

Arata Fukushima - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic cardiomyopathy

Palmitic acid

Relationship Between Early Cardiac Catheterization following Cardiac Arrest Resuscitation and Acute Kidney Injury

Anne V Grossestreuer - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute renal failure

N/A

Acute Reduction of Ambient Air Pressure Lowers Systemic Vascular Resistance and Improves Cardiac Output in Mice in-vivo

Vaibhav B Patel - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

Isoflurane

Compression-to-Ventilation Ratio and Incidence of Rearrest: A Secondary Analysis of the ROC CCC Trial

Robert Schmicker - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

A Single-Site Sensitivity Analysis of the Trial of Continuous or Interrupted Chest Compressions During CPR

Ron Straight - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

N/A

Continuous Quality Review of ICU CPR Events: Performance, Outcomes and Effect of Systems-Level Changes

Eva Seligman - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic obstructive pulmonary disease

N/A

First Trimester Human Umbilical Cord Perivascular Cells (FTM HUCPVCs) Maintain High Expression Levels of Angiogenic Factors and Have Superior Pro-angiogenic Effects on Endothelial Networks When Compared to Term HUCPVCs and BMSCs in an ex-vivo Rat Aortic R

Peter Szaraz - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

GDNF

The Association Between Diabetes Status and Survival Following an Out-of-Hospital Cardiac Arrest: A Retrospective Cohort Study

Sarah Brennenstuhl - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cardiac arrest

N/A

Thrombin Activatable Fibrinolysis Inhibitor is a Regulator of Angiogenic Potential in Endothelial Cells

Jennifer L Balun - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Coronary Artery Disease

Thrombomodulin alfa

Incidence and Clinical Implications of Pneumonia in Comatose Survivors of Out-of-hospital Cardiac Arrest: Insights From University of Ottawa Heart Institute Cardiac Arrest Registry

Hany Rizk - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Arrhythmia

Piperacillin/tazobactam

Filters

28841 Abstracts